• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer" by Lan WG et al.

作者信息

Yavas G, Yavas C, Akyurek S

机构信息

Department of Radiation Oncology, Selcuk University, 42075, Konya, Turkey.

Department of Radiation Oncology, Ankara University, Ankara, Turkey.

出版信息

Clin Transl Oncol. 2018 Jun;20(6):801-802. doi: 10.1007/s12094-017-1775-2. Epub 2017 Oct 23.

DOI:10.1007/s12094-017-1775-2
PMID:29063355
Abstract
摘要

相似文献

1
Comment on "Serum human epididymis protein 4 is associated with the treatment response of concurrent chemo-radiotherapy and prognosis in patients with locally advanced non-small cell lung cancer" by Lan WG et al.
Clin Transl Oncol. 2018 Jun;20(6):801-802. doi: 10.1007/s12094-017-1775-2. Epub 2017 Oct 23.
2
Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.血清人附睾蛋白4与局部晚期非小细胞肺癌患者同步放化疗的治疗反应及预后相关。
Clin Transl Oncol. 2016 Apr;18(4):375-80. doi: 10.1007/s12094-015-1375-y. Epub 2015 Sep 2.
3
Radical Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: When Should Concurrent Chemoradiotherapy Not Be Used?局部晚期非小细胞肺癌的根治性放疗：何时不应采用同步放化疗？
Clin Oncol (R Coll Radiol). 2016 Nov;28(11):708-711. doi: 10.1016/j.clon.2016.07.011. Epub 2016 Aug 9.
4
Phase II study. Concurrent chemotherapy and radiotherapy with nitroglycerin in locally advanced non-small cell lung cancer.II期研究。局部晚期非小细胞肺癌同步化疗及放疗联合硝酸甘油治疗
Radiother Oncol. 2014 May;111(2):311-5. doi: 10.1016/j.radonc.2014.01.021. Epub 2014 May 14.
5
Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development.局部晚期非小细胞肺癌的放化疗联合治疗：现状与未来发展
Crit Rev Oncol Hematol. 2008 Dec;68(3):222-32. doi: 10.1016/j.critrevonc.2008.05.007. Epub 2008 Jul 15.
6
Role of consolidation chemotherapy after concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer.同步放化疗后巩固化疗在局部晚期非小细胞肺癌中的作用。
J Thorac Oncol. 2014 Jan;9(1):e7-8. doi: 10.1097/JTO.0000000000000035.
7
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.空腹血糖是同期放化疗治疗局部晚期非小细胞肺癌患者生存的独立预测因子。
BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5.
8
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.标准剂量与高剂量适形放疗联合并巩固使用卡铂加紫杉醇，联合或不联合西妥昔单抗治疗IIIA期或IIIB期非小细胞肺癌患者（RTOG 0617）：一项随机、二乘二析因3期研究。
Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.
9
The predictive value of F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.F-FDG PET-CT对局部晚期非小细胞肺癌患者接受新诱导治疗（低剂量分割放疗联合同步化疗）后临床结局的预测价值
Radiat Oncol. 2017 Jan 5;12(1):4. doi: 10.1186/s13014-016-0737-0.
10
Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.代谢肿瘤体积在重复18F-FDG PET/CT上对同步放化疗治疗的局部晚期非小细胞肺癌生存早期预测的价值
J Nucl Med. 2014 Oct;55(10):1584-90. doi: 10.2967/jnumed.114.142919. Epub 2014 Sep 11.

本文引用的文献

1
HE4 expression in lung cancer, a meta-analysis.肺癌中HE4的表达：一项荟萃分析
Clin Chim Acta. 2017 Jul;470:109-114. doi: 10.1016/j.cca.2017.05.007. Epub 2017 May 9.
2
Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.血清人附睾蛋白4与局部晚期非小细胞肺癌患者同步放化疗的治疗反应及预后相关。
Clin Transl Oncol. 2016 Apr;18(4):375-80. doi: 10.1007/s12094-015-1375-y. Epub 2015 Sep 2.
3
Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer.
血清人附睾蛋白4（HE4）作为肺癌男性患者的肿瘤标志物。
Clin Chem Lab Med. 2014 Nov;52(11):1639-48. doi: 10.1515/cclm-2014-0041.
4
Elevated human epididymis protein 4 concentrations in chronic kidney disease.人附睾蛋白 4 浓度在慢性肾脏病中的升高。
Ann Clin Biochem. 2012 Jul;49(Pt 4):377-80. doi: 10.1258/acb.2011.011258. Epub 2012 Jun 11.
5
WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung.WFDC2（人附睾蛋白4）：在口腔和呼吸道的固有免疫以及肺腺癌发生发展中的潜在作用
Respir Res. 2006 Apr 6;7(1):61. doi: 10.1186/1465-9921-7-61.